Wealthstreet Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wealthstreet Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-400	Closed	-$33K	–	72
2021 Q2	$33K	Sell	400 -25,918	-98%	-$2.05M	0.17%	62
2021 Q1	$1.99M	Sell	26,318 -820	-3%	-$67K	0.19%	119
2020 Q4	$2.38M	Buy	27,138 +2,720	+11%	+$216K	0.24%	96
2020 Q3	$1.86M	Buy	24,418 +17,065	+232%	+$1.73M	0.21%	107
2020 Q2	$907K	Hold	7,353	–	–	0.11%	149
2020 Q1	$621K	Sell	7,353 -20	-0.3%	-$1.72K	0.09%	164
2019 Q4	$623K	Sell	7,373 -2,000	-21%	-$151K	0.07%	210
2019 Q3	$696K	Sell	9,373 -1,700	-15%	-$131K	0.09%	184
2019 Q2	$948K	Hold	11,073	–	–	0.12%	153
2019 Q1	$984K	Sell	11,073 -2	-0%	-$185	0.13%	145
2018 Q4	$1.03M	Sell	11,075 -500	-4%	-$47.6K	0.14%	137
2018 Q3	$1.12M	Hold	11,575	–	–	0.14%	140
2018 Q2	$1.09M	Hold	11,575	–	–	0.14%	141
2018 Q1	$939K	Buy	11,575 +500	+5%	+$42.9K	0.12%	158
2017 Q4	$988K	Buy	+11,075	New	+$963K	0.12%	156

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Wealthstreet Investment Advisors's BMRN Position: Q3 2021 in Review

Wealthstreet Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2021, closing a stake of 400 shares — an estimated $33K sold.

Wealthstreet Investment Advisors first reported a position in BMRN in Q4 2017 and held it in 15 quarters. The position peaked at $2.38M in Q4 2020. 513 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

Wealthstreet Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Wealthstreet Investment Advisors sold 400 BioMarin Pharmaceuticals shares in Q3 2021, an estimated $33K.
Wealthstreet Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 15 quarters.
Wealthstreet Investment Advisors's BioMarin Pharmaceuticals position peaked at $2.38M in Q4 2020.
513 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Wealthstreet Investment Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.